Transcatheter Arterial Chemoembolization with Hepasphere 30–60 μm for Treatment of Unresectable Hepatocellular Carcinoma | ||
| Benha Medical Journal | ||
| Article 4, Volume 42, Issue 6, June 2025, Pages 31-40 PDF (681.83 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bmfj.2024.325547.2219 | ||
| Authors | ||
| Ahmed Farid Yousef1; Talal Ahmed Amer2; Ahmed El-Sayed Bona* 3; Sherif Ahmed Elrefai Abdelsatar4 | ||
| 1Professor of Diagnostic & Interventional Radiology, Faculty of Medicine, Benha University | ||
| 2Professor of Diagnostic & Interventional Radiology, Faculty of Medicine, Mansoura University | ||
| 3(M.B.B.CH., M.Sc.) | ||
| 4Lecturer of Diagnostic & Interventional Radiology, Faculty of Medicine, Benha University | ||
| Abstract | ||
| Background: Hepatocellular carcinoma (HCC) is the sixth most common malignancy in the world and second leading cause of cancer related death. Management is mainly accomplished by local ablative therapies that can compete in efficiency with surgical resection. This study aimed to assess the safety and efficacy of hepasphere 30-60 μm for the treatment of unresectable HCC. Methods: This prospective study was conducted on 50 patients with unresectable HCC who were selected for the treatment by transcatheter arterial chemoembolization (TACE) therapy with hepasphere 30 – 60 μm (drug eluting beads), at the Egyptian Liver Hospital, Sherbin, Dakahlia. All studied cases were subjected to laboratory studies and imaging studies including Abdominal ultrasonography and Doppler, abdominal triphasic CT. Results: There was highly significant decrease in serum AFP level one, three and six months after treatment compared to pre-treatment level with (P-value < 0.001). There was no insitu recurrence occurred with the first three months after the procedure, but after six months there were five patients (10%) showed insitu recurrence and there was no denovo recurrence occurred till the end of the study. There was a insignificant relation between response and sex (P=0.031), affected hepatic segment number (VI and VIII) (P0.001, 0.027). Conclusion: This study suggests of high evidence of efficacy and safety of hepasphere 30-60 µm in treating patient with Unresectable HCC. Tumor response, number of HCC foci, patient age, serum Alpha Fetoprotein level, and complications due to TACE had a significant effect on survival in HCC treated with TACE. | ||
| Keywords | ||
| Transcatheter Arterial Chemoembolization; Hepasphere; 30–60 μm; Unresectable; Hepatocellular Carcinoma | ||
|
Statistics Article View: 119 PDF Download: 129 |
||
